<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152280</url>
  </required_header>
  <id_info>
    <org_study_id>V2.0</org_study_id>
    <nct_id>NCT02152280</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke</brief_title>
  <official_title>A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Bozhiyin T&amp;S Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Bozhiyin T&amp;S Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research topic.&#xD;
&#xD;
        -  A clinical trial of Danhong injection in treating acute ischemic stroke .&#xD;
&#xD;
      Research purpose.&#xD;
&#xD;
      - To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke&#xD;
      by a randomized, double-blind, multi-center, placebo-controlled clinical trial.&#xD;
&#xD;
      Research design.&#xD;
&#xD;
      - A randomized, double-blind, multi-center, placebo-controlled clinical trial.&#xD;
&#xD;
      Subject crowd.&#xD;
&#xD;
      - Accord with standard of western medicine diagnosis of acute cerebral infarction, stroke and&#xD;
      blood stasis type of traditional Chinese medicine syndrome differentiation.&#xD;
&#xD;
      Sample size. - Total sample size of 320 patients, experimental group, control group is equal&#xD;
      to 1 to 1.&#xD;
&#xD;
      Interim analysis.&#xD;
&#xD;
      - Interim analysis will be performed when the total number of included patients up to half of&#xD;
      the sample size ,160 cases, and according to the interim analysis results to estimate the&#xD;
      sample size and adjust the project adaptively.&#xD;
&#xD;
      Course of treatment.&#xD;
&#xD;
      - 10 days.&#xD;
&#xD;
      Research endpoint.&#xD;
&#xD;
      - The 90th day after the medication for the first time.&#xD;
&#xD;
      Observation index.&#xD;
&#xD;
        1. General condition; the physical and chemical inspection related;&#xD;
&#xD;
        2. Efficacy check : mRS, BI, NIHSS;&#xD;
&#xD;
        3. Safety check: blood routine, urine routine, stool OB, liver function(ALT、AST), renal&#xD;
           function (BUN, Cr), coagulation four indices（PT、APTT、TT、FIB), electrocardiogram.&#xD;
&#xD;
      Efficacy evaluation. 1. The main efficacy index: a. Percentage comparisons of two group&#xD;
      patients of modified Rankin 0-2 grades on the 90th day.&#xD;
&#xD;
      Statistical analysis technique.&#xD;
&#xD;
      - Statistical analysis using SAS 9.2 system, all the statistical test adopted bilateral&#xD;
      inspection, P value less than or equal to 0.05 will be considered a statistically significant&#xD;
      difference.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research topic. - A clinical trial of Danhong injection in treating acute ischemic stroke .&#xD;
&#xD;
      Research purpose.&#xD;
&#xD;
        -  To evaluate the efficacy and safety of Danhong injection in treating acute ischemic&#xD;
           stroke by a randomized, double-blind, multi-center, placebo-controlled clinical trial.&#xD;
&#xD;
      Research design. - A randomized, double-blind, multi-center, placebo-controlled clinical&#xD;
      trial.&#xD;
&#xD;
      Subject crowd. - Accord with standard of western medicine diagnosis of acute cerebral&#xD;
      infarction, stroke and blood stasis type of traditional Chinese medicine syndrome&#xD;
      differentiation.&#xD;
&#xD;
      Sample size.&#xD;
&#xD;
      - Total sample size of 320 patients, experimental group, control group is equal to 1 to 1.&#xD;
&#xD;
      Interim analysis.&#xD;
&#xD;
      - Interim analysis will be performed when the total number of included patients up to half of&#xD;
      the sample size ,160 cases, and according to the interim analysis results to estimate the&#xD;
      sample size and adjust the project adaptively.&#xD;
&#xD;
      Inclusion criteria.&#xD;
&#xD;
        1. Accord with the diagnostic criteria of cerebral infarction of &quot;Guide of diagnosis and&#xD;
           treatment of acute ischemic stroke in China&quot; in 2010, and in the acute stage;&#xD;
&#xD;
        2. Accord with the stroke and blood stasis type;&#xD;
&#xD;
        3. Onset of acute ischemic stroke within 72 hours;&#xD;
&#xD;
        4. NIHSS grade ≥ 4;&#xD;
&#xD;
        5. Age ≥ 18;&#xD;
&#xD;
        6. signed the inform consent form.&#xD;
&#xD;
      Exclusion criteria.&#xD;
&#xD;
        1. Diagnosed with bleeding or other pathological brain disorders according to CT or MRI at&#xD;
           baseline , such as vascular malformation, tumor, abscess or other common non ischemic&#xD;
           cerebral disease (for multiple sclerosis);&#xD;
&#xD;
        2. Patients with hrombolysis or endovascular treatment;&#xD;
&#xD;
        3. Allergic constitution; the test drug allergy or its ingredients or elements allergy;&#xD;
&#xD;
        4. With severe liver function damage(ALT and AST level more than 1.5 times higher than&#xD;
           normal);&#xD;
&#xD;
        5. With severe renal impairment (more than 1.5 times higher than normal amount of serum&#xD;
           creatinine);&#xD;
&#xD;
        6. With severe cardiac insufficiency (cardiac function rating level III above);&#xD;
&#xD;
        7. Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and&#xD;
           physical disabilities caused by other reasons which affects the nerve function defect&#xD;
           evaluation);&#xD;
&#xD;
        8. With bleeding tendency or had serious bleeding within 3 months;&#xD;
&#xD;
        9. Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of&#xD;
           enrollment or complicate the enrollment according to the investigaters' judgement;&#xD;
&#xD;
       10. Menstrual period women, pregnant women and lactating women, pregnancy test positive or&#xD;
           recent family planning;&#xD;
&#xD;
       11. Who being in other clinical trials or had finished other clinical trials within 3&#xD;
           months.&#xD;
&#xD;
           Dosage regimen.&#xD;
&#xD;
           1. Experimental group: Danhong injection 40 ml add 250 ml of 0.9% sodium chloride&#xD;
           solution, injection intravenous drip, 1 time a day, for 10 days; 2. Control group : 0.9%&#xD;
           sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection&#xD;
           intravenous drip, 1 time a day, for 10 days.&#xD;
&#xD;
           Course of treatment.&#xD;
&#xD;
             -  10 days.&#xD;
&#xD;
           Research endpoint.&#xD;
&#xD;
           - The 90th day after the medication for the first time.&#xD;
&#xD;
           Observation index.&#xD;
&#xD;
        1. General condition; the physical and chemical inspection related;&#xD;
&#xD;
        2. Efficacy check : mRS, BI, NIHSS;&#xD;
&#xD;
        3. Safety check: blood routine, urine routine, stool OB, liver function(ALT、AST), renal&#xD;
           function (BUN, Cr), coagulation four indices（PT、APTT、TT、FIB), electrocardiogram.&#xD;
&#xD;
      Observation point.&#xD;
&#xD;
        1. The physical and chemical inspection related and electrocardiogram observed at the&#xD;
           enrollment time;&#xD;
&#xD;
        2. General condition and efficacy index observed on the 10th ,90th after the medication for&#xD;
           the first time;&#xD;
&#xD;
        3. Safety index observed on the 10th after the medication for the first time.&#xD;
&#xD;
      Efficacy evaluation.&#xD;
&#xD;
        1. The main efficacy index:&#xD;
&#xD;
             1. Percentage comparisons of two group patients of modified Rankin 0-2 grades on the&#xD;
                90th day.&#xD;
&#xD;
        2. The secondary efficacy index:&#xD;
&#xD;
             1. Mortality comparisons of two group patients on the 90th day;&#xD;
&#xD;
             2. Percentage comparisons of two group patients of BI≥75 on the 90th day;&#xD;
&#xD;
             3. NIHSS difference comparisons of two group on the 90th day;&#xD;
&#xD;
             4. The proportion of new vascular events within 3 months (Ischemic stroke/hemorrhagic&#xD;
                stroke/TIA/MI/vascular death).&#xD;
&#xD;
      Safety evaluation.&#xD;
&#xD;
        1. All-Cause mortality within 90 days :the death toll of all cause within 90 days/ the&#xD;
           total number of each group × 100%;&#xD;
&#xD;
        2. Incidence of serious bleeding events (GUSTO definition, appendix 4), including fatal&#xD;
           bleeding and symptomatic intracranial bleeding;&#xD;
&#xD;
        3. Incidence of moderate bleeding events (GUSTO definition, appendix 4);&#xD;
&#xD;
        4. Adverse events and serious adverse events reported by investigaters.&#xD;
&#xD;
      Statistical analysis technique.&#xD;
&#xD;
      - Statistical analysis using SAS 9.2 system, all the statistical test adopted bilateral&#xD;
      inspection, P value less than or equal to 0.05 will be considered a statistically significant&#xD;
      difference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.</measure>
    <time_frame>0-90 day</time_frame>
    <description>Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Danhong Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danhong Injection</intervention_name>
    <description>Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.</description>
    <arm_group_label>Danhong Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Accord with the diagnostic criteria of cerebral infarction of &quot;Guide of diagnosis and&#xD;
             treatment of acute ischemic stroke in China&quot; in 2010, and in the acute stage;&#xD;
&#xD;
          -  Accord with the stroke and blood stasis type;&#xD;
&#xD;
          -  Onset of acute ischemic stroke within 72 hours;&#xD;
&#xD;
          -  NIHSS grade ≥ 4;&#xD;
&#xD;
          -  Age ≥ 18;&#xD;
&#xD;
          -  signed the inform consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with bleeding or other pathological brain disorders according to CT or MRI&#xD;
             at baseline , such as vascular malformation, tumor, abscess or other common non&#xD;
             ischemic cerebral disease (for multiple sclerosis);&#xD;
&#xD;
          -  Patients with hrombolysis or endovascular treatment;&#xD;
&#xD;
          -  Allergic constitution; the test drug allergy or its ingredients or elements allergy;&#xD;
&#xD;
          -  With severe liver function damage(ALT and AST level more than 1.5 times higher than&#xD;
             normal);&#xD;
&#xD;
          -  With severe renal impairment (more than 1.5 times higher than normal amount of serum&#xD;
             creatinine);&#xD;
&#xD;
          -  With severe cardiac insufficiency (cardiac function rating level III above)&#xD;
&#xD;
          -  Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and&#xD;
             physical disabilities caused by other reasons which affects the nerve function defect&#xD;
             evaluation);&#xD;
&#xD;
          -  With bleeding tendency or had serious bleeding within 3 months;&#xD;
&#xD;
          -  Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of&#xD;
             enrollment or complicate the enrollment according to the investigaters' judgement;&#xD;
&#xD;
          -  Menstrual period women, pregnant women and lactating women, pregnancy test positive or&#xD;
             recent family planning;&#xD;
&#xD;
          -  Who being in other clinical trials or had finished other clinical trials within 3&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang D Cai, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Traditional Chinese medicine department of Zhongshan Hospital</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

